Argus raised the firm’s price target on Cardinal Health (CAH) to $189 from $185 and keeps a Buy rating on the shares. The company is executing well with all of its segments delivering double digit profit growth in Q4 and FY25, the analyst tells investors in a research note. Shares are trading below Cardinal’s peers, but the recent weakness in the stock presents a buying opportunity, Argus adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health CEO sells $16.04M in common stock
- Cardinal Health Secures $1 Billion in Notes Sale
- Cardinal Health price target raised to $203 from $197 at Baird
- Cardinal Health price target raised to $185 from $183 at Wells Fargo
- Cardinal Health’s Growth Potential: Buy Rating Reaffirmed Amid Strong Pharma Performance and Strategic Focus